Sarepta Therapeutics (SRPT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$22.50-2.13%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SRPT
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-09-04.
The screen ranks SRPT against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 3 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on executing commercial strategy, advancing siRNA pipeline with clinical readouts, and delivering sustainable long-term value.
Stated as a priority in 3 of last 3 quarters. Net product revenues were $330.5 million in 2026-Q1 and $328.7 million in 2026-Q2, showing stable commercial performance. The siRNA pipeline advanced with first Phase 1/2 data for SRP-1001 and SRP-1003 in 2026-Q1 and ongoing clinical readouts expected in 2H 2026. Management is delivering on commercial execution and pipeline advancement.
“Our priorities are clear: execute our commercial strategy, advance our promising siRNA pipeline, and continue allocating capital with discipline.”
“Advancing a pipeline that we believe can define Sarepta's next era, with encouraging early signals in DM1 and FSHD and multiple upcoming readouts.”
“Poised for meaningful growth while advancing therapies that can profoundly change the lives of patients living with rare disease.”
Maintain profitability and positive cash flow throughout 2026 to support pipeline and operations.
Stated as a priority in 4 of last 4 quarters. Sarepta delivered GAAP operating income of $358.4 million in 2026-Q1 and $13.3 million in 2026-Q2, with net income positive in Q1 but negative in Q2. Cash and equivalents increased from $748.3 million in Q1 to $945.0 million in Q2. Management is delivering profitability and cash flow positivity with some quarterly variability.
“Delivered another quarter of operating profitability and ended with approximately $945.0 million of cash.”
Control combined non-GAAP research and development and selling, general and administrative expenses within $800 million to $900 million range for 2026.
Stated as a priority in 3 of last 3 quarters. Management narrowed combined non-GAAP R&D and SG&A expense guidance from $800-$900 million to $800-$850 million for 2026. This reflects a focus on cost discipline. Actual expense figures for the first half of 2026 show decreases consistent with this guidance. The trajectory is delivering on cost control.
“Narrowing combined non-GAAP R&D and SG&A expense guidance from $800.0-$900.0 million to $800.0-$850.0 million.”
Progress siRNA pipeline programs including DM1, FSHD, and Huntington's disease with clinical data readouts expected in 2026.
Stated as a priority in 3 of last 3 quarters. Sarepta advanced siRNA programs with Phase 1/2 data for DM1 and FSHD in 2026-Q1 and dosing underway for Huntington's disease Phase 1 study in 2026-Q2. Management expects multiple clinical readouts in 2H 2026. The trajectory is delivering clinical progress consistent with stated goals.
Grow ELEVIDYS sales through Japan launch and plans to re-include non-ambulatory patients via enhanced immunosuppression regimen.
Stated as a priority in 3 of last 3 quarters. ELEVIDYS net product revenue was $102.0 million in 2026-Q1 and $98.1 million in 2026-Q2, reflecting stable sales. The Japan launch milestone of $40 million was achieved in 2026-Q1. Enrollment for ENDEAVOR Cohort 8 to expand to non-ambulatory patients is underway with data expected in early 2027. Management is delivering on commercial expansion plans.
Over the trailing year it converted 31.14x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
21 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.
“Strong first quarter of 2026 financial performance delivering GAAP and Non-GAAP operating profit.”
“We anticipate remaining profitable and cash-flow positive in 2026.”
“Underlying operations were cash flow positive when excluding planned Arrowhead collaboration payments.”
“Reiterate FY 2026 combined non-GAAP R&D and SG&A expenses of $800.0 - $900.0 million.”
“Combined non-GAAP R&D and SG&A expenses of $800.0 - $900.0 million guidance for 2026.”
“Readouts from MAD cohorts in DM1 and FSHD remain on track for 2H 2026; dosing underway in Huntington's disease Phase 1 study.”
“First clinical data from siRNA pipeline targeting FSHD1 and DM1 showed dose-dependent drug exposure and favorable tolerability.”
“Five clinical-stage RNAi programs with multiple readouts ahead, poised for meaningful growth.”
“Full enrollment of ENDEAVOR Cohort 8 expected by year-end 2026; 12-week data from full cohort in Q1 2027.”
“ELEVIDYS first commercial sale in Japan; milestone payment of $40 million earned.”
“ENDEAVOR Cohort 8 to evaluate enhanced immunosuppression regimen for non-ambulant individuals approved to begin.”